Elixirgen, LLC forms two subsidiary companies - Elixirgen Scientific, LLC and Elixirgen Therapeutics, LLC

BALTIMORE, February 21, 2017 - Elixirgen, LLC announced that it has formed two subsidiary companies, Elixirgen Scientific, LLC and Elixirgen Therapeutics, LLC, in Q4 of 2016.

Elixirgen Scientific will focus on the development and sale of regenerative medicine products for use in both the lab and clinic. The company aims to strike at one of the industry’s top issues today - the high cost and inefficiencies in iterating research and development due to the time required to differentiate cells from human pluripotent stem cells (hPSCs) to specific human cells. Since differentiated cells are the starting material for experiments in personalized medicine or large-scale drug screening efforts, delays in this process are a significant cost to biotechnology and pharmaceutical companies working in those fields. Elixirgen Scientific’s latest Quick-TissueTM Series line of stem cell differentiation kits are an affordable, all-in-one solution that reduces differentiation time from over a month to one week - available now at elixirgenscientific.com.

Elixirgen Therapeutics is a company that is dedicated to finding cures and therapies for genetic diseases, and then developing them into drugs to treat patients. The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic research and translational research approaches to meet its goals. Elixirgen Therapeutics’ drug development pipeline will be available soon on its website, elixirgentherapeutics.com.

Elixirgen Scientific, LLC and Elixirgen Therapeutics, LLC, are located in the Science + Technology Park at Johns Hopkins in Baltimore next to their parent company. The Science + Technology Park at Johns Hopkins is an ideal research environment that allows Elixirgen Group scientists to conduct research at state-of-the-art facilities.

New Quick-Tissue™ Kits Revolutionize Skeletal Muscle and Neuron Differentiation

BALTIMORE, October 3, 2016 – Elixirgen, LLC, a Baltimore-based biotechnology company, today launched Quick-Muscle™ 1.0, a groundbreaking biological reagent that develops skeletal muscle cells from human stem cells in just a few days — a cutting-edge advancement for a laboratory process that previously took a month or longer.

Pre-orders are also being taken for Quick-Neuron™ 1.0, the fastest and most efficient neuron differentiation kit ever available. Quick-Neuron™ 1.0 yields an abundance of neurons in less than one week and will be available in November.

The Quick-Muscle™ 1.0 cocktail allows skeletal muscle cells to be rapidly and efficiently produced from human embryonic stem cells and induced pluripotent stem cells in only four to five days. Quick-Muscle™ 1.0 is the fastest and most effective product on the market. Quick-Muscle™ 1.0 provides fast access to the skeletal muscle cells needed to explore treatments by drug screening or possible cell transplantation therapy for muscle-related diseases such as muscular dystrophy. The possibilities for this innovative technology are endless.

Quick-Muscle™ 1.0 and Quick-Neuron™ 1.0 transform laboratory work. Scientists now have a much more rapid turn-around time, allowing for greater efficiency and larger-scale research.

Elixirgen holds the exclusive license and proprietary technologies for Quick-Muscle™ and other Quick-Tissue™ products.

Quick-Muscle™ 1.0 is now available for purchase in the U.S. here. Quick-Neuron™ 1.0 is available for pre-order in the U.S. here.

About Elixirgen:

Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology.

CONTACT: Info@elixirgen.com

Elixirgen Signs License Agreement with National Institute on Aging, NIH

BALTIMORE, May 16, 2016 – Elixirgen has entered into a license agreement with the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH).

This sublicensable license agreement involves several patents that enable Elixirgen to develop, manufacture, and market research reagents that are based on the gene ZSCAN4. The reagents are used to treat pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

The technologies behind these patents were co-invented by Dr. Minoru Ko, Elixirgen’s co-founder and chief scientific officer, while he served as senior investigator and section chief at the Intramural Research Program, the internal research program of the NIH.

This license agreement fortifies Elixirgen’s existing patent portfolios regarding ZSCAN4, a gene in which Elixirgen specializes and which holds great therapeutic promise.

About Elixirgen:

Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology.

About the National Institute on Aging:

The NIA leads the federal government effort conducting and supporting research on aging and the health and well-being of older people. The Institute’s broad scientific program seeks to understand the nature of aging and to extend the healthy, active years of life. For more information on research, aging, and health, go to www.nia.nih.gov.

About the National Institutes of Health (NIH):

NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Elixirgen Secures Exclusive Patent License Agreement with Keio University in Japan

BALTIMORE, May 16, 2016 – Elixirgen, LLC, announced today that it has entered into a worldwide exclusive license agreement with Keio University in Tokyo.

The agreement gives Elixirgen exclusive access to several key technologies developed at Keio University that allow for the efficient differentiation of human pluripotent stem cells into a variety of usable cell types, such as skeletal muscles and neurons.

Dr. Minoru Ko, Elixirgen’s co-founder and chief scientific officer, is a co-inventor of the technologies through his work at the Department of Systems Medicine at the Keio University School of Medicine. The technologies allow for the creation of rapid and scalable generations of functionally mature and relatively homogenous differentiated cells, which can be used for drug screening to identify therapeutic compounds, disease modeling to further study molecular mechanisms underlying the diseases, and cell replacement therapy in regenerative medicine.

About Elixirgen:

Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology.

About Keio University:

Keio University is a private, higher education institution located in the Greater Tokyo area. It offers an environment of academic and research excellence, and includes a university hospital. Founded in 1858, it is Japan’s first modern institution of higher learning, and over the last century and a half it has established itself as a leader in Japan through its continued commitment to education, research and medicine. Additional information about Keio University is available at www.keio.ac.jp.

Elixirgen Announces License Agreement with Sumitomo Dainippon Pharma

tube.jpg

BALTIMORE, Nov. 19, 2015 — Elixirgen, LLC, a growing biotechnology company in Baltimore, announced today that it has entered an exclusive license agreement with Sumitomo Dainippon Pharma Co., Ltd., a major pharmaceutical company in Japan.

The agreement will focus on Elixirgen’s research regarding biologics targeting diseases associated with genome instability and chromosome abnormalities. Sumitomo Dainippon Pharma will gain exclusive rights for the further research (in part), development, and commercialization of the biologics in the region of Japan. Elixirgen will receive an upfront payment. In addition, Elixirgen is eligible to receive payments for development milestones, and royalties and milestones on the commercial sales of approved products in Japan. Outside of Japan, Elixirgen retains all rights.

“We are excited to work with one of the leading pharmaceutical companies in Japan for development and commercialization of our biologics in Japan. We believe this agreement will help accelerate our transition to clinical trials for our therapies,” said Naomi Ko, CEO of Elixirgen.

About Elixirgen:

Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as the treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology. Additional information about Elixirgen is available at elixirgen.com.

About Sumitomo Dainippon Pharma:

Sumitomo Dainippon Pharma’s goal is to create innovative pharmaceutical products. Psychiatry & Neurology as well as Oncology represent our focus therapeutic areas containing significant unmet medical needs. It is channeling its R&D energies also into two new fields: diseases where no approved drugs exist as well as regenerative medicine/cell therapy. Additional information about Sumitomo Dainippon Pharma is available at www.ds-pharma.com.

CONTACT: Vanessa Harrington, 443-869-5420, harrington.vanessa@elixirgen.com

Source: Elixirgen, LLC

New Down Syndrome therapy discovered

BALTIMORE, Aug. 31, 2015 PRNewswire — For people with Down syndrome, news from Elixirgen, LLC may brighten their day. The biotechnology company, located in the Science + Technology Park at Johns Hopkins, has outlined one of the best potential therapies yet for people with Down syndrome and other chromosome disorders in a paper entitled, “Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures,” published in the journal DNA Research. Elixirgen plans to develop this technology into a treatment for the many complications that affect people with Down syndrome and other chromosome disorders at all age levels.

The paper demonstrates the use of the gene ZSCAN4 as a means to cure chromosome abnormalities. First, the company’s researchers developed footprint-free ways to deliver ZSCAN4 into cells; the gene is expressed in a transient manner. Next, they found that such “hit-and-run” application of the gene significantly increased the proportion of cells with a normal number of chromosomes – also known as euploidy – in a population of mouse embryonic stem cells with mostly abnormal numbers of chromosomes – also known as aneuploidy. Finally, the researchers used the human version of the same gene on cells from people with Down syndrome and Edwards syndrome and found a significant increase in the number of euploid cells. Because Down syndrome and Edwards syndrome are caused by having three copies of a chromosome (21 and 18 respectively), the euploid cells no longer have the characteristics of either of those syndromes. Interestingly, ZSCAN4 is found ordinarily in the 2-cell stage of mammalian embryos and occasionally in stem cells, making the gene a natural chromosome therapy.

People with Down syndrome often experience a range of complications such as congenital heart defects, blood disorders and cognitive impairment. These complications can be less severe in people with mosaic Down syndrome – a form of Down syndrome where the person has a mixture of euploid and aneuploid cells instead of all aneuploid cells.

“Our goal is to alleviate the complications in people with Down syndrome by using ZSCAN4 therapy to increase their numbers of euploid cells,” says Dr. Minoru Ko, Elixirgen’s Chief Scientific Officer.

The company is currently focusing on bringing the Down syndrome therapy into the clinic. However, because there are many other chromosome disorders that are without a sufficient treatment, their discovery of aneuploidy correction may offer a lead to more cures in the future.

About Elixirgen, LLC:

Elixirgen is a biotechnology company based in Baltimore, Maryland at the Science + Technology Park at Johns Hopkins. Founded in January 2012, Elixirgen’s objective is to develop therapies for genetic and rare diseases and make them accessible and affordable for all.

Amano T, Jeffries E, Amano M, Ko AC, Yu H, Ko MSH: Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures. DNA Research, doi:10.1093/dnares/dsv016

CONTACT: Akihiro Ko, 443-869-5420, info@elixirgen.com

Source: Elixirgen, LLC